https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-refractory-acute-myeloid-leukemia-likelihood-of-approval/
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase I for Refractory Acute Myeloid Leukemia.
bristol myers squibbacute myeloid leukemiaonuregrefractory
https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-relapsed-acute-myeloid-leukemia-likelihood-of-approval/
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsed Acute Myeloid Leukemia.
bristol myers squibbacute myeloid leukemiaonuregrelapsed